^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rhIL-15

    i
    Other names: rhIL-15
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    CD8 T-cell agonist, CD4 T cell modulator
    Related drugs:
    Associations

    News

    Trials
    21d
    Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. (PubMed, Front Immunol)
    Correlative assays suggest significant immunological effects of amputation and chemotherapy on immune responses. These data have important implications on novel immunotherapy strategies involving multimodality approaches including surgery and chemotherapy.
    P2 data • Journal • IO biomarker
    |
    IL6 (Interleukin 6) • IL15 (Interleukin 15)
    |
    rhIL-15
    5ms
    A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies. (PubMed, Blood Neoplasia)
    Recombinant human interleukin-15 (rhIL-15) is an immunotherapeutic agent that enhances natural killer (NK) cells to augment the antibody-dependent cellular cytotoxicity (ADCC) of monoclonal antibodies. Future development of combinations of immunotherapy that target the microenvironment in relapsed or refractory T-cell lymphomas remains rational. This trial was registered at www.ClinicalTrials.gov as #NCT04185220.
    Clinical • P1 data • Journal
    |
    IL15 (Interleukin 15)
    |
    Poteligeo (mogamulizumab-kpkc) • rhIL-15
    7ms
    Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (clinicaltrials.gov)
    P1, N=31, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=50 --> 31 | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2025 --> Nov 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    11ms
    Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (clinicaltrials.gov)
    P1, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    almost2years
    Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (clinicaltrials.gov)
    P1, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    almost3years
    Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (clinicaltrials.gov)
    P1, N=6, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> May 2022
    Trial completion • Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IL15 (Interleukin 15)
    |
    Poteligeo (mogamulizumab-kpkc) • rhIL-15
    almost3years
    Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (clinicaltrials.gov)
    P1, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    3years
    Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (clinicaltrials.gov)
    P1, N=8, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> May 2022
    Trial completion • Trial completion date • Combination therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IL15 (Interleukin 15) • IL5 (Interleukin 5)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • rhIL-15
    over3years
    Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma (clinicaltrials.gov)
    P2, N=2, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.
    Trial termination
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • rhIL-15
    over3years
    Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (clinicaltrials.gov)
    P1, N=1, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; The study was closed after > 1 year of inactivity.
    Trial termination
    |
    IL15 (Interleukin 15)
    |
    Gazyva (obinutuzumab) • rhIL-15
    almost4years
    Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Mar 2022 --> Mar 2021
    Trial primary completion date • Combination therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • rhIL-15
    almost4years
    Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Mar 2025
    Trial completion date • Combination therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • rhIL-15